[{"indications": "Indications\u00a0life-threatening or sight-threatening\r\ncytomegalovirus infections in immunocompromised patients only; prevention\r\nof cytomegalovirus disease during immunosuppressive therapy following\r\norgan transplantation; local treatment of CMV retinitis (section\r\n11.3.3)", "name": "GANCICLOVIR", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.3 Antiviral drugs", "5.3.2 Herpesvirus infections", "5.3.2.2 Cytomegalovirus infection"], "cautions": "Cautions\u00a0close monitoring of full blood count (severe deterioration\r\nmay require correction and possibly treatment interruption); history of cytopenia; potential\r\ncarcinogen and teratogen; radiotherapy; ensure adequate hydration during intravenous\r\nadministration; vesicant\u2014infuse into vein\r\nwith adequate flow preferably using plastic cannula; children\r\n(possible risk of long-term carcinogenic or reproductive toxicity); interactions: Appendix 1 (ganciclovir)", "side-effects": "Side-effects\u00a0diarrhoea, nausea, vomiting, dyspepsia, abdominal\r\npain, constipation, flatulence, dysphagia, taste disturbance, hepatic\r\ndysfunction; dyspnoea, chest pain, cough; headache, insomnia, convulsions,\r\ndizziness, peripheral neuropathy, depression, anxiety, confusion,\r\nabnormal thinking, fatigue, weight loss, anorexia; infection, pyrexia,\r\nnight sweats; anaemia, leucopenia, thrombocytopenia, pancytopenia,\r\nrenal impairment; myalgia, arthralgia; macular oedema, retinal detachment,\r\nvitreous floaters, eye pain; ear pain; dermatitis, pruritus; injection-site\r\nreactions; less commonly mouth ulcers, pancreatitis,\r\narrhythmias, hypotension, anaphylactic reactions, psychosis, tremor,\r\nmale infertility, haematuria, disturbances in hearing and vision,\r\nand alopecia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4005.htm", "doses": ["By intravenous infusion, initially\r\n(induction) 5\u00a0mg/kg every 12 hours for 14\u201321 days for treatment or\r\nfor 7\u201314 days for prevention; maintenance (for patients at risk of\r\nrelapse of retinitis) 6\u00a0mg/kg daily on 5 days per week or 5\u00a0mg/kg daily until adequate recovery of immunity; if retinitis\r\nprogresses initial induction treatment may be repeated; child under 18 years, see BNF for Children"], "pregnancy": "Pregnancy\u00a0avoid\u2014teratogenic risk; ensure effective contraception\r\nduring treatment and barrier contraception for men during\r\nand for at least 90 days after treatment"}, {"indications": "Indications\u00a0local treatment of herpes simplex infections", "name": "GANCICLOVIR - ANTIVIRALS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "11 Eye", "11.3 Anti-infective eye preparations", "11.3.3 Antivirals"], "side-effects": "Side-effects\u00a0burning sensation, tingling, superficial punctate\r\nkeratitis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/202590.htm", "doses": ["Apply 5 times daily until healing complete, then apply\r\n3 times daily for a further 7 days"]}, {"indications": "Indications\u00a0life-threatening or sight-threatening\r\ncytomegalovirus infections in immunocompromised patients only; prevention\r\nof cytomegalovirus disease during immunosuppressive therapy following\r\norgan transplantation; local treatment of CMV retinitis (section\r\n11.3.3)", "name": "GANCICLOVIR - CYTOMEGALOVIRUS INFECTION", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.3 Antiviral drugs", "5.3.2 Herpesvirus infections", "5.3.2.2 Cytomegalovirus infection"], "cautions": "Cautions\u00a0close monitoring of full blood count (severe deterioration\r\nmay require correction and possibly treatment interruption); history of cytopenia; potential\r\ncarcinogen and teratogen; radiotherapy; ensure adequate hydration during intravenous\r\nadministration; vesicant\u2014infuse into vein\r\nwith adequate flow preferably using plastic cannula; children\r\n(possible risk of long-term carcinogenic or reproductive toxicity); interactions: Appendix 1 (ganciclovir)", "side-effects": "Side-effects\u00a0diarrhoea, nausea, vomiting, dyspepsia, abdominal\r\npain, constipation, flatulence, dysphagia, taste disturbance, hepatic\r\ndysfunction; dyspnoea, chest pain, cough; headache, insomnia, convulsions,\r\ndizziness, peripheral neuropathy, depression, anxiety, confusion,\r\nabnormal thinking, fatigue, weight loss, anorexia; infection, pyrexia,\r\nnight sweats; anaemia, leucopenia, thrombocytopenia, pancytopenia,\r\nrenal impairment; myalgia, arthralgia; macular oedema, retinal detachment,\r\nvitreous floaters, eye pain; ear pain; dermatitis, pruritus; injection-site\r\nreactions; less commonly mouth ulcers, pancreatitis,\r\narrhythmias, hypotension, anaphylactic reactions, psychosis, tremor,\r\nmale infertility, haematuria, disturbances in hearing and vision,\r\nand alopecia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4005.htm", "doses": ["By intravenous infusion, initially\r\n(induction) 5\u00a0mg/kg every 12 hours for 14\u201321 days for treatment or\r\nfor 7\u201314 days for prevention; maintenance (for patients at risk of\r\nrelapse of retinitis) 6\u00a0mg/kg daily on 5 days per week or 5\u00a0mg/kg daily until adequate recovery of immunity; if retinitis\r\nprogresses initial induction treatment may be repeated; child under 18 years, see BNF for Children"], "pregnancy": "Pregnancy\u00a0avoid\u2014teratogenic risk; ensure effective contraception\r\nduring treatment and barrier contraception for men during\r\nand for at least 90 days after treatment"}]